123 related articles for article (PubMed ID: 11788908)
1. Effective treatment of experimental DU-145 prostate cancers with targeted cytotoxic somatostatin analog AN-238.
Plonowski A; Schally AV; Nagy A; Sun B; Halmos G
Int J Oncol; 2002 Feb; 20(2):397-402. PubMed ID: 11788908
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238.
Plonowski A; Schally AV; Nagy A; Sun B; Szepeshazi K
Cancer Res; 1999 Apr; 59(8):1947-53. PubMed ID: 10213505
[TBL] [Abstract][Full Text] [Related]
3. Targeting of cytotoxic somatostatin analog AN-238 to somatostatin receptor subtypes 5 and/or 3 in experimental pancreatic cancers.
Szepeshazi K; Schally AV; Halmos G; Sun B; Hebert F; Csernus B; Nagy A
Clin Cancer Res; 2001 Sep; 7(9):2854-61. PubMed ID: 11555603
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin AN-238.
Plonowski A; Schally AV; Nagy A; Kiaris H; Hebert F; Halmos G
Cancer Res; 2000 Jun; 60(11):2996-3001. PubMed ID: 10850448
[TBL] [Abstract][Full Text] [Related]
5. Targeted cytotoxic analogue of somatostatin AN-238 inhibits growth of androgen-independent Dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses.
Koppan M; Nagy A; Schally AV; Arencibia JM; Plonowski A; Halmos G
Cancer Res; 1998 Sep; 58(18):4132-7. PubMed ID: 9751625
[TBL] [Abstract][Full Text] [Related]
6. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
[TBL] [Abstract][Full Text] [Related]
7. Effective treatment of H838 human non-small cell lung carcinoma with a targeted cytotoxic somatostatin analog, AN-238.
Szereday Z; Schally AV; Szepeshazi K; Bajo AM; Hebert F; Halmos G; Nagy A
Int J Oncol; 2003 May; 22(5):1141-6. PubMed ID: 12684683
[TBL] [Abstract][Full Text] [Related]
8. Regression of U-87 MG human glioblastomas in nude mice after treatment with a cytotoxic somatostatin analog AN-238.
Kiaris H; Schally AV; Nagy A; Sun B; Szepeshazi K; Halmos G
Clin Cancer Res; 2000 Feb; 6(2):709-17. PubMed ID: 10690557
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207.
Stangelberger A; Schally AV; Nagy A; Szepeshazi K; Kanashiro CA; Halmos G
Prostate; 2006 Feb; 66(2):200-10. PubMed ID: 16173040
[TBL] [Abstract][Full Text] [Related]
10. Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers.
Bajo AM; Schally AV; Halmos G; Nagy A
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3742-8. PubMed ID: 14506166
[TBL] [Abstract][Full Text] [Related]
11. Effective treatment of experimental androgen sensitive and androgen independent intraosseous prostate cancer with targeted cytotoxic somatostatin analogue AN-238.
Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
J Urol; 2004 Feb; 171(2 Pt 1):911-5. PubMed ID: 14713852
[TBL] [Abstract][Full Text] [Related]
12. Targeted cytotoxic somatostatin analogue AN-238 inhibits somatostatin receptor-positive experimental colon cancers independently of their p53 status.
Szepeshazi K; Schally AV; Halmos G; Armatis P; Hebert F; Sun B; Feil A; Kiaris H; Nagy A
Cancer Res; 2002 Feb; 62(3):781-8. PubMed ID: 11830533
[TBL] [Abstract][Full Text] [Related]
13. Effective treatment of metastatic MDA-MB-435 human estrogen-independent breast carcinomas with a targeted cytotoxic analogue of luteinizing hormone-releasing hormone AN-207.
Chatzistamou L; Schally AV; Nagy A; Armatis P; Szepeshazi K; Halmos G
Clin Cancer Res; 2000 Oct; 6(10):4158-65. PubMed ID: 11051271
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of human non-small cell lung cancers with a targeted cytotoxic somatostatin analog, AN-162.
Treszl A; Schally AV; Seitz S; Szalontay L; Rick FG; Szepeshazi K; Halmos G
Peptides; 2009 Sep; 30(9):1643-50. PubMed ID: 19524629
[TBL] [Abstract][Full Text] [Related]
15. Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone-releasing hormone analogues AN-152 and AN-207.
Engel JB; Keller G; Schally AV; Nagy A; Chism DD; Halmos G
Fertil Steril; 2005 Apr; 83 Suppl 1():1125-33. PubMed ID: 15831285
[TBL] [Abstract][Full Text] [Related]
16. Effective inhibition of experimental human ovarian cancers with a targeted cytotoxic bombesin analogue AN-215.
Engel JB; Keller G; Schally AV; Halmos G; Hammann B; Nagy A
Clin Cancer Res; 2005 Mar; 11(6):2408-15. PubMed ID: 15788692
[TBL] [Abstract][Full Text] [Related]
17. Preclinical evaluation of therapeutic effects of targeted cytotoxic analogs of somatostatin and bombesin on human gastric carcinomas.
Szepeshazi K; Schally AV; Nagy A; Wagner BW; Bajo AM; Halmos G
Cancer; 2003 Oct; 98(7):1401-10. PubMed ID: 14508826
[TBL] [Abstract][Full Text] [Related]
18. Growth inhibition of experimental non-Hodgkin's lymphomas with the targeted cytotoxic somatostatin analogue AN-238.
Keller G; Engel JB; Schally AV; Nagy A; Hammann B; Halmos G
Int J Cancer; 2005 May; 114(5):831-5. PubMed ID: 15609311
[TBL] [Abstract][Full Text] [Related]
19. Targeted cytotoxic analogue of bombesin/gastrin-releasing peptide inhibits the growth of H-69 human small-cell lung carcinoma in nude mice.
Kiaris H; Schally AV; Nagy A; Sun B; Armatis P; Szepeshazi K
Br J Cancer; 1999 Nov; 81(6):966-71. PubMed ID: 10576652
[TBL] [Abstract][Full Text] [Related]
20. Indirect antiproliferative effect of the somatostatin analog octreotide on MIA PaCa-2 human pancreatic carcinoma in nude mice.
Weckbecker G; Raulf F; Bodmer D; Bruns C
Yale J Biol Med; 1997; 70(5-6):549-54. PubMed ID: 9825482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]